Free Design Audit Available - Click Here for Details

FDA clears pulsed field ablation electrode tech from Pulse Biosciences

Pulse Biosciences (Nasdaq:PLSE) announced that the FDA granted 510(k) clearance for its CellFX nsPFA percutaneous electrode system.

The Hayward, California-based company develops the CellFX nanosecond pulsed field ablation (nsPFA) system. Its percutaneous electrode system enables the ablation of soft tissue in percutaneous and intraoperative surgical procedures.

CellFX nsPFA’s percutaneous electrode system features a percutaneous needle electrode for use with the proprietary CellFX console. The company designed the novel electrode to harness and deliver the key advantages of nsPFA energy. It enables the precise, nonthermal removal of cellular tissue without damaging noncellular structures or inducing thermal necrosis.

Sign up for Blog Updates